Novo Nordisk (NVO)

• Market cap: $214B
• 1 day: -2.45%
• 5 days: -8.63%
• 1 month: -19.08%
• 3 months: -1.15%
• 6 months: -30.19%
• Year to date: -44.87%
• 1 year: -56.02%
• 5 years: 47.87%
• 10 years: 77.85%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Employees: 78,387